Go to content

New opioid use in older adults with COPD associated with increased risk of cardiac death


Older adults with chronic obstructive pulmonary disorder (COPD) who recently started using opioids have an increased risk of coronary artery disease-related death compared to non-opioid users, researchers have found.

Among these patients, new opioid use is associated with a 215 percent increase in coronary artery disease-related death for long-term care residents and an 83 percent increase in coronary artery disease-related death for those who lived at home compared to non-opioid users, according to the study.

The study, published today in the European Journal of Clinical Pharmacology, raises concerns about new opioid use among older adults with COPD, a progressive lung disease that causes breathing difficulty, said Dr. Nicholas Vozoris, a respirologist at St. Michael’s and lead author of the study.

Previous research by Dr. Vozoris found older adults with COPD who recently started using opioids are also at an increased risk of dying from respiratory reasons compared to non-opioid users.

COPD affects approximately four to 10 per cent of the Canadian population, with the five-year mortality rate from 40 to 70 per cent, depending on the severity. The two-year mortality rate for people with severe COPD is about 50 per cent.

The researchers looked at the records of more than 130,000 community-dwelling adults and more than 14,000 long-term care residents in Ontario age 66 and older with COPD, using multiple provincial healthcare administrative databases housed at the Institute for Clinical Evaluative Sciences (ICES).

“Previous research has shown about 70 percent of older adults with COPD use opioids, which is an incredibly high rate of new use in a population that is potentially more sensitive to narcotics,” said Dr. Vozoris. “Our new findings show there are not only increased risks for coronary artery disease-related death associated with new opioid use, but also increased risk of cardiac-related visits to emergency rooms and hospitalizations.”

Dr. Vozoris found that 60 per cent of older adults with COPD living in the community and 67 per cent of long-term care residents were given a new opioid between April 2008 and March 2013. Opioids, including morphine and fentanyl, are prescribed frequently among older adults with COPD to help treat chronic muscle and bone pain, insomnia, as well as persisting cough and shortness of breath despite inhaler therapy.

“This class of drugs may offer some relief for this population, but there is also evidence suggesting that opioids can adversely affect cardiac health,” said Dr. Vozoris.

Researchers looked specifically at opioids that were not combined with either Aspirin or Tylenol.

Opioids are known to potentially lower blood oxygen levels and increase blood carbon dioxide levels, and these alterations can have negative effects on the heart, according to Dr. Vozoris. Opioids are also known to potentially increase inflammatory factors in the blood vessels, which can cause blockages and cause a heart attack, he said.

While the findings don’t prove cause and effect, only an association between new opioid use and an increased risk of coronary artery disease-related death, researchers hypothesized that it could be related to these potential side effects.

“One other important reason they might be linked to future risk of heart attacks is because they offer pain relief, which could reduce or take away chest pain that acts as a warning before a cardiac event,” said Dr. Vozoris. “Without that warning, doctors may not be able to intervene in time.”

Dr. Vozoris said he hoped that clinicians would take these findings into consideration when prescribing opioids to people with COPD.

“Coronary artery disease-related death is another potential risk of prescribing an opioid to an already high-risk population,” he said. “I hope that providers will be more careful about prescribing opioids to COPD patients, and that patients are made aware of the risks so they can be vigilant about potential side effects.”

This research was funded by a Godfrey S. Pettit Respirology Block Term Grant.

About St. Michael's Hospital

St. Michael’s Hospital provides compassionate care to all who enter its doors. The hospital also provides outstanding medical education to future healthcare professionals in 29 academic disciplines. Critical care and trauma, heart disease, neurosurgery, diabetes, cancer care, care of the homeless and global health are among the hospital’s recognized areas of expertise. Through the Keenan Research Centre and the Li Ka Shing International Healthcare Education Centre, which make up the Li Ka Shing Knowledge Institute, research and education at St. Michael's Hospital are recognized and make an impact around the world. Founded in 1892, the hospital is fully affiliated with the University of Toronto.

The Institute for Clinical Evaluative Sciences (ICES) is an independent, non-profit organization that uses population-based health information to produce knowledge on a broad range of healthcare issues. Our unbiased evidence provides measures of health system performance, a clearer understanding of the shifting healthcare needs of Ontarians, and a stimulus for discussion of practical solutions to optimize scarce resources. ICES knowledge is highly regarded in Canada and abroad, and is widely used by government, hospitals, planners, and practitioners to make decisions about care delivery and to develop policy. For the latest ICES news, follow us on Twitter: @ICESOntario

For more information, or to arrange an interview with one of the authors, please contact:

Kelly O’Brien
Communications Advisor – Media
[email protected]
St. Michael’s Hospital
Inspired Care. Inspiring Science.
Follow us on Twitter: http://www.twitter.com/stmikeshospital

Deborah Creatura
Media Advisor, ICES
[email protected]
(o) 416-480-4780 or (c) 647-406-5996

Read the Journal Article